Compare Phillips 66 (PSX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Repligen Corporation Common Stock — how do they compare? Phillips 66 trades at $297.04 (market cap $116.81B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Phillips 66 is far larger — about 10.5× Repligen Corporation Common Stock's market cap, and Phillips 66 pays a 1.74% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 63 Days and Repligen Corporation Common Stock for 0 Days on average.
| PSX | RGEN | |
|---|---|---|
Market Cap | $116.81B | $11.14B |
Volume | 2,609,145 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $297.29 | $194.57 |
52-Week Low | $127.75 | $102.87 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $133.27B | $11.02B |
Dividend Yield | 1.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $297.29, up 5.62% on the day, showing strong momentum near recent highs. The stock demonstrates solid fundamentals with a P/E of 16.71 and P/S of 0.78, while recent earnings beats and a 24.02% ROE highlight operational strength. Technical indicators show bullish momentum with the current price above key support levels. Recent news highlights structural advantages in refining margins and AI implementation for operational efficiency.
PSX presents a compelling investment case with strong profitability metrics and positive analyst sentiment (54% buy ratings), though current price exceeds the $286.90 consensus target. Key risks include refining margin volatility and potential policy impacts on diesel exports. The company's debt reduction progress and projected 2026 net cash flow of $3.0B support the bullish outlook despite competitive pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
